Literature DB >> 34758313

Single-cell transcriptomics reveals opposing roles of Shp2 in Myc-driven liver tumor cells and microenvironment.

Wendy S Chen1, Yan Liang1, Min Zong2, Jacey J Liu1, Kota Kaneko1, Kaisa L Hanley1, Kun Zhang3, Gen-Sheng Feng4.   

Abstract

The mechanisms of Myc-driven liver tumorigenesis are inadequately understood. Herein we show that Myc-driven hepatocellular carcinoma (HCC) is dramatically aggravated in mice with hepatocyte-specific Ptpn11/Shp2 deletion. However, Myc-induced tumors develop selectively from the rare Shp2-positive hepatocytes in Shp2-deficent liver, and Myc-driven oncogenesis depends on an intact Ras-Erk signaling promoted by Shp2 to sustain Myc stability. Despite a stringent requirement of Shp2 cell autonomously, Shp2 deletion induces an immunosuppressive environment, resulting in defective clearance of tumor-initiating cells and aggressive tumor progression. The basal Wnt/β-catenin signaling is upregulated in Shp2-deficient liver, which is further augmented by Myc transfection. Ablating Ctnnb1 suppresses Myc-induced HCC in Shp2-deficient livers, revealing an essential role of β-catenin. Consistently, Myc overexpression and CTNNB1 mutations are frequently co-detected in HCC patients with poor prognosis. These data elucidate complex mechanisms of liver tumorigenesis driven by cell-intrinsic oncogenic signaling in cooperation with a tumor-promoting microenvironment generated by disrupting the specific oncogenic pathway.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Shp2; cMyc; hepatocellular carcinoma; macrophages; single cell RNA sequencing; tumor-promoting microenvironment

Mesh:

Substances:

Year:  2021        PMID: 34758313      PMCID: PMC8656042          DOI: 10.1016/j.celrep.2021.109974

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  67 in total

1.  LECT2, a Ligand for Tie1, Plays a Crucial Role in Liver Fibrogenesis.

Authors:  Meng Xu; Hong-Hai Xu; Yuan Lin; Xiangnan Sun; Li-Jing Wang; Zhe-Ping Fang; Xue-Han Su; Xiang-Jing Liang; Yang Hu; Zhi-Min Liu; Yuanxiong Cheng; Yuanyuan Wei; Jiabin Li; Li Li; Hong-Juan Liu; Zhiqiang Cheng; Na Tang; Chao Peng; Tingting Li; Tengfei Liu; Liang Qiao; Dalei Wu; Yan-Qing Ding; Wei-Jie Zhou
Journal:  Cell       Date:  2019-08-29       Impact factor: 41.582

2.  Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.

Authors:  Tikvah K Hayes; Nicole F Neel; Chaoxin Hu; Prson Gautam; Melissa Chenard; Brian Long; Meraj Aziz; Michelle Kassner; Kirsten L Bryant; Mariaelena Pierobon; Raoud Marayati; Swapnil Kher; Samuel D George; Mai Xu; Andrea Wang-Gillam; Ahmed A Samatar; Anirban Maitra; Krister Wennerberg; Emanuel F Petricoin; Hongwei H Yin; Barry Nelkin; Adrienne D Cox; Jen Jen Yeh; Channing J Der
Journal:  Cancer Cell       Date:  2015-12-24       Impact factor: 31.743

3.  Shp2 deletion in hepatocytes suppresses hepatocarcinogenesis driven by oncogenic β-Catenin, PIK3CA and MET.

Authors:  Jacey J Liu; Yanjie Li; Wendy S Chen; Yan Liang; Gaowei Wang; Min Zong; Kota Kaneko; Ruiyun Xu; Michael Karin; Gen-Sheng Feng
Journal:  J Hepatol       Date:  2018-03-02       Impact factor: 25.083

4.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

5.  A genome-wide screen for beta-catenin binding sites identifies a downstream enhancer element that controls c-Myc gene expression.

Authors:  Gregory S Yochum; Ryan Cleland; Richard H Goodman
Journal:  Mol Cell Biol       Date:  2008-10-13       Impact factor: 4.272

6.  Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.

Authors:  Ying-Nan P Chen; Matthew J LaMarche; Ho Man Chan; Peter Fekkes; Jorge Garcia-Fortanet; Michael G Acker; Brandon Antonakos; Christine Hiu-Tung Chen; Zhouliang Chen; Vesselina G Cooke; Jason R Dobson; Zhan Deng; Feng Fei; Brant Firestone; Michelle Fodor; Cary Fridrich; Hui Gao; Denise Grunenfelder; Huai-Xiang Hao; Jaison Jacob; Samuel Ho; Kathy Hsiao; Zhao B Kang; Rajesh Karki; Mitsunori Kato; Jay Larrow; Laura R La Bonte; Francois Lenoir; Gang Liu; Shumei Liu; Dyuti Majumdar; Matthew J Meyer; Mark Palermo; Lawrence Perez; Minying Pu; Edmund Price; Christopher Quinn; Subarna Shakya; Michael D Shultz; Joanna Slisz; Kavitha Venkatesan; Ping Wang; Markus Warmuth; Sarah Williams; Guizhi Yang; Jing Yuan; Ji-Hu Zhang; Ping Zhu; Timothy Ramsey; Nicholas J Keen; William R Sellers; Travis Stams; Pascal D Fortin
Journal:  Nature       Date:  2016-06-29       Impact factor: 49.962

7.  Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer.

Authors:  Stefano Cairo; Carolina Armengol; Aurélien De Reyniès; Yu Wei; Emilie Thomas; Claire-Angélique Renard; Andrei Goga; Asha Balakrishnan; Michaela Semeraro; Lionel Gresh; Marco Pontoglio; Hélène Strick-Marchand; Florence Levillayer; Yann Nouet; David Rickman; Frédéric Gauthier; Sophie Branchereau; Laurence Brugières; Véronique Laithier; Raymonde Bouvier; Françoise Boman; Giuseppe Basso; Jean-François Michiels; Paul Hofman; Francine Arbez-Gindre; Hélène Jouan; Marie-Christine Rousselet-Chapeau; Dominique Berrebi; Luc Marcellin; François Plenat; Dominique Zachar; Madeleine Joubert; Janick Selves; Dominique Pasquier; Paulette Bioulac-Sage; Michael Grotzer; Margaret Childs; Monique Fabre; Marie-Annick Buendia
Journal:  Cancer Cell       Date:  2008-12-09       Impact factor: 31.743

8.  SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models.

Authors:  Carmine Fedele; Hao Ran; Brian Diskin; Wei Wei; Jayu Jen; Mitchell J Geer; Kiyomi Araki; Ugur Ozerdem; Diane M Simeone; George Miller; Benjamin G Neel; Kwan Ho Tang
Journal:  Cancer Discov       Date:  2018-07-25       Impact factor: 39.397

9.  A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer.

Authors:  Daniel Dauch; Ramona Rudalska; Giacomo Cossa; Jean-Charles Nault; Tae-Won Kang; Torsten Wuestefeld; Anja Hohmeyer; Sandrine Imbeaud; Tetyana Yevsa; Lisa Hoenicke; Tatu Pantsar; Przemyslaw Bozko; Nisar P Malek; Thomas Longerich; Stefan Laufer; Antti Poso; Jessica Zucman-Rossi; Martin Eilers; Lars Zender
Journal:  Nat Med       Date:  2016-05-23       Impact factor: 53.440

10.  SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors.

Authors:  Tamer A Ahmed; Christos Adamopoulos; Zoi Karoulia; Xuewei Wu; Ravi Sachidanandam; Stuart A Aaronson; Poulikos I Poulikakos
Journal:  Cell Rep       Date:  2019-01-02       Impact factor: 9.423

View more
  3 in total

1.  Temporal analyses of postnatal liver development and maturation by single-cell transcriptomics.

Authors:  Yan Liang; Kota Kaneko; Bing Xin; Jin Lee; Xin Sun; Kun Zhang; Gen-Sheng Feng
Journal:  Dev Cell       Date:  2022-02-07       Impact factor: 12.270

2.  Recent insights into the pathogeneses and therapeutic targets of liver diseases: Summary of the 4th Chinese American Liver Society/Society of Chinese Bioscientists in America Hepatology Division Symposium in 2021.

Authors:  Wen-Xing Ding; Hua Wang; Yuxia Zhang
Journal:  Liver Res       Date:  2022-01-29

Review 3.  Targeting protein phosphatases for the treatment of inflammation-related diseases: From signaling to therapy.

Authors:  Jie Pan; Lisha Zhou; Chenyang Zhang; Qiang Xu; Yang Sun
Journal:  Signal Transduct Target Ther       Date:  2022-06-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.